Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan may be forced to divest more than Inamed's development-stage botulinum toxin type A product, Reloxin.